< Back to previous page
Researcher
Patrik Verstreken
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Behavioural neuroscience
- Disciplines (KU Leuven):Neurological and neuromuscular diseases
Affiliations
- Research Group Molecular Neurobiology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Responsible
From1 Jan 2008 → Today - Laboratory of Neuronal Communication (VIB-KU Leuven) (Lab)
Member
From1 Jan 2017 → Today - VIB-KU LEUVEN CENTER FOR BRAIN & DISEASE RESEARCH (Research Center)
Responsible
From1 Jan 2017 → Today - VERSTREKEN LAB (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 63
See also Patrik Verstreken for projects of Flanders Institute for Biotechnology.
Here below the projects of KU Leuven.
- Targeting synaptic dysfunction in dementiaFrom1 Oct 2025 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- The impact of intracranial pressure on neuronal healthFrom29 Sep 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Disruption of vesicle transport as a pathogenic mechanism in Parkinson's diseaseFrom1 Jan 2025 → TodayFunding: Other federal public and semi-governmental institutions
- Antisense oligonucleotides as therapeutics for Autosomal Dominant Alzheimer’s DiseaseFrom1 Jan 2025 → TodayFunding: Other federal public and semi-governmental institutions
- Microglia and Synaptic Plasticity: Uncovering Hibernation Mechanisms to Combat NeurodegenerationFrom7 Oct 2024 → TodayFunding: FWO fellowships
- Identification of synaptic targets for the treatment of tauopathiesFrom1 Oct 2024 → TodayFunding: FWO junior postdoctoral fellowship
- Sleep-like activity on multielectrode array (MEA)-chip for Parkinson's disease (SLAM-PD).From1 Oct 2024 → 31 Jul 2025Funding: FWO senior postdoctoral fellowship
- Extreme synaptic plasticity: mechanisms of synapse loss and regeneration during hibernationFrom16 Sep 2024 → TodayFunding: FWO fellowships
- Physiological role of Tau in sleepFrom10 Jul 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Tau-dependent synaptic remodeling in health and diseaseFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 158
See also Patrik Verstreken for publications of Flanders Institute for Biotechnology.
Here below the publications of KU Leuven.
- Soma-localized Rab39 inhibits synaptic autophagy by controlling trafficking of Atg9 vesicles(2025)Published in: EMBO JournalISSN: 0261-4189Issue: 20Volume: 44Pages: 5662 - 5693
- Compartement-Specific Inhibition of Synaptic Autophagy: Rab39-Mediated Regulation of Atg9 Vesicle Trafficking(2025)
- Discovery and Characterization of a Selective Inhibitor of Synaptojanin1 5-Phosphatase Activity(2025)Published in: ACS Pharmacol Transl SciISSN: 2575-9108Issue: 9Volume: 8Pages: 2996 - 3006
- A conserved epilepsy-associated gene co-expression module identifies increased metabolic rate as a shared pathomechanism.(2025)Published in: Disease Models and MechanismsISSN: 1754-8403Pages: dmm.052307
- Synaptic deregulation of cholinergic projection neurons causes olfactory dysfunction across 5 fly Parkinsonism models(2025)Published in: ElifeISSN: 2050-084XVolume: 13
- Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health(2024)Published in: Journal of Cell BiologyISSN: 0021-9525Issue: 2Volume: 224
- A candidate loss-of-function variant in SGIP1 causes synaptic dysfunction and recessive parkinsonism(2024)Published in: CELL REPORTS MEDICINEISSN: 2666-3791Issue: 10Volume: 5
- Drosophila appear resistant to trans-synaptic tau propagation(2024)Published in: Brain CommunicationsISSN: 2632-1297Issue: 4Volume: 6
- Elevated α-synuclein levels inhibit mitophagic flux(2024)Published in: npj Parkinsons DiseaseISSN: 2373-8057Issue: 1Volume: 10
- Molecular basis for the role of EndoA1 and SGIP1 in synaptic homeostasis and Parkinson's disease(2023)
Patents
1 - 10 of 10
- Oligonucleotides for modulating synaptogyrin-3 expression
- Compounds for treatment of intractable epilepsy and doors syndrome
- Screening method for synaptogyrin-3 inhibitors
- Targeting synaptogyrin-3 in tauopathy treatment
- Targeting synaptogyrin-3 in tauopathy treatment
- Means and methods for treatment of early-onset parkinson's disease
- Means and methods for treatment of early-onset parkinson's disease
- Targeting synaptogyrin-3 in tauopathy treatment
- Compounds for treatment of intractable epilepsy and doors syndrome
- Restoring phosphorylation of a novel pink1 substrate to treat parkinson's disease